Literature DB >> 8536619

Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically.

A L Schneyer1, H A Hall, G Lambert-Messerlian, Q F Wang, P Sluss, W F Crowley.   

Abstract

Follistatin (FS) is the principle high affinity activin-binding protein in tissues such as the pituitary and ovary as well as in serum. In addition, the activin-binding peaks identified after gel filtration of serum or human follicular fluid (hFF) exhibited high affinity and low reversibility binding kinetics, with higher concentrations in hFF than serum. This extremely low reversibility was also observed for recombinant human follistatin 288 (rhFS288) under a variety of incubation conditions, further supporting the identification of the serum and hFF activin-binding proteins as FS. Using enhanced resolution gel filtration, immunoprecipitation with monoclonal antibodies to rhFS288, and sulfated carbohydrate binding, activin-FS complexes in hFF and serum differed. The activin-FS complex in hFF elutes at approximately 200-300 kDa, is immunoprecipitated by anti-hFS288 monoclonal antibodies, and binds to sulfate Cellufine matrix, all characteristics similar to those of recombinant human FS288. In contrast, the activin binding peak in human serum elutes at an apparent Mr of 60-70 kDa, is no precipitated by anti-rhFS288 monoclonal antibodies, and is weakly bound by sulfate Cellufine matrix, characteristics shared by rhFS315 conditioned medium. As the forms of FS that bind sulfate-containing matrices also bind to cell surface proteoglycans, the molecular differences reported here for serum and hFF activin-binding proteins have implications for potential tissue-specific forms of FS that may well have distinct biological functions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8536619     DOI: 10.1210/endo.137.1.8536619

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Differential effects of aging on activin A and its binding protein, follistatin, across the menopause transition.

Authors:  Nancy E Reame; Jane L Lukacs; Pamela Olton; Rudi Ansbacher; Vasantha Padmanabhan
Journal:  Fertil Steril       Date:  2007-04-16       Impact factor: 7.329

Review 2.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 3.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

Review 4.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

5.  Growth differentiation factor 9 (GDF9) suppresses follistatin and follistatin-like 3 production in human granulosa-lutein cells.

Authors:  Feng-Tao Shi; Anthony P Cheung; He-Feng Huang; Peter C K Leung
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

6.  The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Mohammed Ashshi
Journal:  BMC Res Notes       Date:  2015-06-26

Review 7.  Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Authors:  Bassem Refaat; Ahmed Mohamed Ashshi; Adel Galal El-Shemi; Esam Azhar
Journal:  Mediators Inflamm       Date:  2015-04-19       Impact factor: 4.711

8.  Role of activins in embryo implantation and diagnosis of ectopic pregnancy: a review.

Authors:  Bassem Refaat
Journal:  Reprod Biol Endocrinol       Date:  2014-11-25       Impact factor: 5.211

9.  Pegylated Interferon-α Modulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar Rat.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Mohamed Ashshi; Elaf Wael Mahamid; Noha Mohammed Al-Qadi
Journal:  Mediators Inflamm       Date:  2015-07-06       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.